- Conditions
- Generalized Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), Separation Anxiety Disorder, Specific Phobia, Obsessive Compulsive Disorder (OCD), Panic Disorder (With or Without Agoraphobia)
- Interventions
- Relaxation and Mentorship Training (RMT), Stepped Care Targeting Exposure and Parenting for Anxiety (STEP-A)
- Behavioral
- Lead sponsor
- Andrew Wiese
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2041–2064
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Asthma
- Interventions
- FP, LABA, LTRA, LAMA, Theophylline, Oral Corticosteroids
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 483 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mission Viejo, California • Sacramento, California + 26 more
- Conditions
- Meningitis, Meningococcal
- Interventions
- MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 15 Years to 25 Years
- Enrollment
- 1,250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 48
- States / cities
- Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
- Conditions
- Geographic Atrophy
- Interventions
- APL-2, Sham Procedure
- Drug · Other
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 67
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 56 more
- Conditions
- Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cardiovascular Diseases
- Interventions
- Cardiovascular Magnetic Resonance
- Diagnostic Test
- Lead sponsor
- Dipan Shah
- Other
- Eligibility
- Not listed
- Enrollment
- 100,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2058
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Recurrent Parathyroid Carcinoma
- Interventions
- Ultrasound-guided RFA
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer
- Interventions
- Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody, Cobimetinib, Regorafenib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 363 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 17
- States / cities
- Duarte, California • New Haven, Connecticut • Washington D.C., District of Columbia + 14 more
- Conditions
- Phenylketonuria (PKU)
- Interventions
- BMN165 20mg/day, BMN165 40mg/day, Placebo
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 29
- States / cities
- La Jolla, California • Oakland, California • Aurora, Colorado + 26 more
- Conditions
- Endometriosis
- Interventions
- OG-6219, Placebo
- Drug
- Lead sponsor
- Organon and Co
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 354 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, Connecticut + 22 more
- Conditions
- Progressive Supranuclear Palsy(PSP)
- Interventions
- AADvac1, LM11A-31
- Biological · Drug
- Lead sponsor
- Adam Boxer
- Other
- Eligibility
- 41 Years to 86 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 24
- States / cities
- Sun City, Arizona • Los Angeles, California • Palo Alto, California + 18 more
- Conditions
- Neuroblastoma, Medulloblastoma
- Interventions
- Nifurtimox, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 15
- States / cities
- San Diego, California • Hartford, Connecticut • Orlando, Florida + 12 more
- Conditions
- Covid19
- Interventions
- STRI Formula, Placebo
- Drug
- Lead sponsor
- Eyecheck, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 598 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 13
- States / cities
- Coral Gables, Florida • Doral, Florida • Medley, Florida + 4 more
- Conditions
- Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- amphotericin B deoxycholate, nystatin
- Drug
- Lead sponsor
- Aronex Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2007
- U.S. locations
- 59
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
- Conditions
- Trauma Injury, Pain, Opioid Use
- Interventions
- Ketamine plus usual care, Usual Care
- Drug
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Neoplasms
- Interventions
- Regorafenib (Stivarga, BAY73-4506)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,010 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 17
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Gainesville, Florida + 13 more
- Conditions
- Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)
- Interventions
- AZD1775, Olaparib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 5
- States / cities
- Denver, Colorado • Sarasota, Florida • New York, New York + 2 more
- Conditions
- Fecal Incontinence
- Interventions
- TOPAS Treatment for Fecal Incontinence
- Device
- Lead sponsor
- ASTORA Women's Health
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 14
- States / cities
- San Francisco, California • Tampa, Florida • Weston, Florida + 11 more
- Conditions
- Liver Cancer
- Interventions
- Magnetic Resonance Elastogram, 2-Point Dixon Magnetic Resonance Imaging
- Diagnostic Test
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Phase 1b, HC-7366, SHARK, Kidney Cancer
- Interventions
- Nivolumab, HC-7366, ipilimumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Houston, Texas
- Conditions
- Locally Recurrent Breast Cancer, Metastatic Breast Cancer
- Interventions
- NKTR-102, Treatment of Physician's Choice (TPC)
- Drug
- Lead sponsor
- Nektar Therapeutics
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 852 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 88
- States / cities
- Flagstaff, Arizona • Burbank, California • Los Angeles, California + 74 more
- Conditions
- Cardiovascular Disease
- Interventions
- Olpasiran, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years to 105 Years
- Enrollment
- 11,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 206
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 168 more
- Conditions
- Chronic Spontaneous Urticaria (CSU)
- Interventions
- Remibrutinib, Remibrutinib matching placebo, Dupilumab, Placebo solution for injection
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 409 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Litchfield Park, Arizona • Payson, Arizona + 98 more
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
- Interventions
- Delafloxacin, Linezolid, Vancomycin
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Buena Park, California + 27 more